Business
APIC25 Annual Conference attendance
APIC25 Annual Conference attendance.
About this update from Tristel Plc
[{"type":"text","content":"\n\nTRISTEL plc\n(\"Tristel\" or the \"Company\")\n \nAPIC25 Annual Conference attendance\n \nTristel Exhibits at the Largest Annual Infection Prevention Event in the U.S. and Launches Tristel OPH Following FDA Clearance\n \nTristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces its successful participation at APIC 2025, the largest annual infection prevention and control conference in the United States, and the official U.S. launch of Tristel OPH, a novel high-level disinfectant for ophthalmic instruments, following clearance by the U.S. Food and Drug Administration (FDA).\n \nAPIC 2025 provided a high-impact platform for Tristel to introduce Tristel OPH to the U.S. market. The product addresses a significant unmet need in ophthalmology, offering a solution that combines compliance with infection control guidelines and improved clinical workflow efficiency. Its debut generated exceptional interest from infection prevention professionals, reflecting the urgency for effective, practical alternatives in the reprocessing of ophthalmic medical devices.\n \nA robust pipeline of prospective customers has already been established, with many health systems engaging directly with the Tristel team during the event for live demonstrations and discussions on product evaluation. Stock availability is expected in August 2025, and Tristel is actively supporting U.S. institutions in preparing for clinical trials and internal validation upon launch.\n \nIn addition to Tristel OPH, the Company also showcased Tristel ULT, its FDA-cleared high level disinfectant for ultrasound probes, represented by Tristel's distribution partner and ultrasound specialist, Parker Laboratories, Inc., and Tristel 3T, the Company's digital traceability platform. Both products attracted strong interest from new prospects and existing users alike, with particular enthusiasm shown for Tristel ULT's cost-effectiveness and rapid reprocessing capabilities.\n \nThe strong reception at APIC 2025 reinforces Tristel's accelerating momentum in the U.S. and underlines the increasing demand for innovative and compliant high level disinfection solutions in medical device reprocessing.\n \n [\n \nMatt Sassone, CEO of Tristel plc, said: \"APIC 2025 marked a significant milestone for our U.S. strategy. Th...